SCHEMBL5453663

SCHEMBL5453663

NC(=O)c1c(NC(=O)Nc2cccnc2Cl)sc2c1CCOC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.54
CFTR P13569 1/20 0.53
KCNH2 Q12809 4/20 0.48
ANO1 Q5XXA6 3/20 0.48
FLT3 P36888 2/20 0.48
RAB9A P51151 4/20 0.46
CNR2 P34972 3/20 0.46
NPC1 O15118 3/20 0.46
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CNR1 P21554 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PTPRC P08575 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPRB P23467 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460654 0.86 ANO1 (0.64) CFTRKCNH2ANO1RAB9ACNR2
SCHEMBL5458458 0.84 CFTR (0.57) HPGDCFTRKCNH2ANO1FLT3
SCHEMBL5455040 0.84 CFTR (0.55) CFTRKCNH2ANO1FLT3RAB9A
SCHEMBL5448477 0.83 CFTR (0.58) CFTRKCNH2ANO1FLT3RAB9A
SCHEMBL5449480 0.82 CFTR (0.58) CFTRKCNH2ANO1FLT3RAB9A
SCHEMBL5467763 0.82 CFTR (0.58) HPGDCFTRKCNH2ANO1RAB9A
SCHEMBL5457966 0.82 ANO1 (0.66) CFTRANO1FLT3RAB9ACNR2
SCHEMBL16962264 0.80 KCNH2 (0.68) CFTRKCNH2ANO1FLT3RAB9A
SCHEMBL5463139 0.80 CFTR (0.55) CFTRKCNH2ANO1FLT3RAB9A
SCHEMBL5456340 0.80 CFTR (0.60) CFTRKCNH2ANO1FLT3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 HPGD 2361/4885CFTR 2030/4885KCNH2 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.